Table 2 Summary and analysis of the proportion of patients achieving sustained (≥ 48 h) symptom alleviation
All patients | < 2 Moderate/higher symptom severity at baseline | ≥ 2 Moderate/higher symptom severity at baseline | ||||
|---|---|---|---|---|---|---|
Placebo (N = 529) | Sotrovimab (N = 528) | Placebo (N = 237) | Sotrovimab (N = 241) | Placebo (N = 214) | Sotrovimab (N = 218) | |
Day 7 | ||||||
Symptom alleviation status, n (%) | ||||||
Sustained (≥ 48 h) symptom alleviation | 31 (6) | 76 (14) | 25 (11) | 52 (22) | 7 (3) | 22 (10) |
Not sustained symptom alleviation | 498 (94) | 452 (86) | 212 (89) | 189 (78) | 207 (97) | 196 (90) |
Adjusted relative risk ratio (95% CI) | 2.51 (1.69 to 3.72) | 2.07 (1.33 to 3.21) | 3.10 (1.36 to 7.07) | |||
p value | < 0.001 | 0.002 | 0.008 | |||
Adjusted relative risk difference | 9.99 | 13.46 | 8.72 | |||
Day 14 | ||||||
Symptom alleviation status, n (%) | ||||||
Sustained (≥ 48 h) symptom alleviation | 104 (20) | 164 (31) | 62 (26) | 96 (40) | 36 (17) | 63 (29) |
Not sustained symptom alleviation | 425 (80) | 364 (69) | 175 (74) | 145 (60) | 178 (83) | 155 (71) |
Adjusted relative risk ratio (95% CI) | 1.59 (1.28 to 1.97) | 1.52 (1.17 to 1.98) | 1.72 (1.20 to 2.47) | |||
p value | < 0.001 | 0.002 | 0.004 | |||
Adjusted relative risk difference | 8.08 | 11.20 | 10.06 | |||
Day 21 | ||||||
Symptom alleviation status, n (%) | ||||||
Sustained (≥ 48 h) symptom alleviation | 178 (34) | 214 (41) | 104 (44) | 126 (52) | 64 (30) | 78 (36) |
Not sustained symptom alleviation | 351 (66) | 314 (59) | 133 (56) | 115 (48) | 150 (70) | 140 (64) |
Adjusted relative risk ratio (95% CI) | 1.21 (1.03 to 1.41) | 1.19 (0.99 to 1.43) | 1.20 (0.92 to 1.57) | |||
p value | 0.020 | 0.072 | 0.188 | |||
Adjusted relative risk difference | 4.37 | 6.31 | 4.61 | |||